Lopez S

References (7)

Title : Toxic effects of the cylindrospermopsin and chlorpyrifos combination on the differentiated SH-SY5Y human neuroblastoma cell line - Hinojosa_2023_Toxicon__107091
Author(s) : Hinojosa MG , Gutierrez-Praena D , Lopez S , Prieto AI , Moreno FJ , Jos A , Camean AM
Ref : Toxicon , :107091 , 2023
Abstract : Due to climate change and anthropogenic activities, the levels of pollution of aquatic and terrestrial environments have increased in the last decades. In this sense, the rise of cyanobacterial blooms, which release secondary metabolites with toxic properties, and the global use of pesticides for agricultural purposes have a negative impact on ecosystems. Thus, it would be interesting to study the concomitance of both types of toxicants in the same sample, since it is possible that they appear together. The aim of the present work was to state the effects of the interaction between the cyanotoxin cylindrospermopsin and the pesticide chlorpyrifos in differentiated SH-SY5Y neuronal cells to assess how they could affect the nervous system. To this end, cytotoxicity, morphological, and acetylcholinesterase activity studies were performed during 24 and 48 h. The results revealed a concentration-dependent decrease in viability and interaction between both toxicants, together with clear signs of apoptosis and necrosis induction. In this sense, different stages on the differentiation process would lead to differences in the toxicity exerted by the compounds both isolated as in combination, which it is not observed in non-differentiated cells. Additionally, the acetylcholinesterase activity appeared not to be affected, which is a clear difference compared to non-differentiated cells. These results show the importance of studying not only the toxicants themselves, but also in combination, to assess their possible effects in a more realistic scenario.
ESTHER : Hinojosa_2023_Toxicon__107091
PubMedSearch : Hinojosa_2023_Toxicon__107091
PubMedID: 36965714

Title : Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease - Yener_2022_Int.J.Psychophysiol__
Author(s) : Yener G , Hunerli-Gunduz D , Yildirim E , Akturk T , Basar-Eroglu C , Bonanni L , Del Percio C , Farina F , Ferri R , Guntekin B , Hajos M , Ibanez A , Jiang Y , Lizio R , Lopez S , Noce G , Parra M , Randall F , Stocchi F , Babiloni C
Ref : Int J Psychophysiol , : , 2022
Abstract : Alzheimer's disease dementia (ADD) is the most diffuse neurodegenerative disorder belonging to mild cognitive impairment (MCI) and dementia in old persons. This disease is provoked by an abnormal accumulation of amyloid-beta and tauopathy proteins in the brain. Very recently, the first disease-modifying drug has been licensed with reserve (i.e., Aducanumab). Therefore, there is a need to identify and use biomarkers probing the neurophysiological underpinnings of human cognitive functions to test the clinical efficacy of that drug. In this regard, event-related electroencephalographic potentials (ERPs) and oscillations (EROs) are promising candidates. Here, an Expert Panel from the Electrophysiology Professional Interest Area of the Alzheimer's Association and Global Brain Consortium reviewed the field literature on the effects of the most used symptomatic drug against ADD (i.e., Acetylcholinesterase inhibitors) on ERPs and EROs in ADD patients with MCI and dementia at the group level. The most convincing results were found in ADD patients. In those patients, Acetylcholinesterase inhibitors partially normalized ERP P300 peak latency and amplitude in oddball paradigms using visual stimuli. In these same paradigms, those drugs partially normalize ERO phase-locking at the theta band (4-7 Hz) and spectral coherence between electrode pairs at the gamma (around 40 Hz) band. These results are of great interest and may motivate multicentric, double-blind, randomized, and placebo-controlled clinical trials in MCI and ADD patients for final cross-validation.
ESTHER : Yener_2022_Int.J.Psychophysiol__
PubMedSearch : Yener_2022_Int.J.Psychophysiol__
PubMedID: 35588964

Title : Interaction between the mGlu receptors 5 antagonist, MPEP, and amphetamine on memory and motor functions in mice - Manago_2013_Psychopharmacology.(Berl)_226_541
Author(s) : Manago F , Lopez S , Oliverio A , Amalric M , Mele A , De Leonibus E
Ref : Psychopharmacology (Berl) , 226 :541 , 2013
Abstract : RATIONALE: Metabotropic glutamate mGlu receptors 5 (mGluR5) receptors are abundant in corticolimbic circuitry where they modulate glutamate and dopamine signal transduction. OBJECTIVES: In this study, we explored the hypothesis that mGluR5 antagonist, (2-methyl-6-(phenylethynyl)pyridine hydrochloride) (MPEP), facilitates dopamine-dependent effects on memory and motor functions.
METHODS: To this aim, we examined the effects of different doses (from 0 to 24 mg/kg) of the mGluR5 antagonist, MPEP, on the modulation of amphetamine-dependent behaviors, namely passive avoidance, locomotor activity, and rotation behavior in intact and dopamine-depleted CD1 male mice.
RESULTS: We demonstrated that a low dose (3 mg/kg) of MPEP, which is void of behavioral effects on its own, facilitates amphetamine-induced effects independently on the behavior measured both in naive and in dopamine-lesioned mice; this synergistic effect is lost when higher doses of MPEP are used. CONCLUSION: The results are discussed in terms of possible balance between dopamine and glutamate activity in regulating the proper fine tuning of information processing.
ESTHER : Manago_2013_Psychopharmacology.(Berl)_226_541
PubMedSearch : Manago_2013_Psychopharmacology.(Berl)_226_541
PubMedID: 23192313

Title : Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity - Texido_2005_Br.J.Pharmacol_145_672
Author(s) : Texido L , Ros E , Martin-Satue M , Lopez S , Aleu J , Marsal J , Solsona C
Ref : British Journal of Pharmacology , 145 :672 , 2005
Abstract : 1. Various types of anticholinesterasic agents have been used to improve the daily activities of Alzheimer's disease patients. It was recently demonstrated that Galantamine, described as a molecule with anticholinesterasic properties, is also an allosteric enhancer of human alpha4beta2 neuronal nicotinic receptor activity. We explored its effect on the human alpha7 neuronal nicotinic acetylcholine receptor (nAChR) expressed in Xenopus oocytes. 2. Galantamine, at a concentration of 0.1 microM, increased the amplitude of acetylcholine (ACh)-induced ion currents in the human alpha7 nAChR expressed in Xenopus oocytes, but caused inhibition at higher concentrations. The maximum effect of galantamine, an increase of 22% in the amplitude of ACh-induced currents, was observed at a concentration of 250 microM Ach. 3. The same enhancing effect was obtained in oocytes transplanted with Torpedo nicotinic acetylcholine receptor (AChR) isolated from the electric organ, but in this case the optimal concentration of galantamine was 1 microM. In this case, the maximum effect of galantamine, an increase of 35% in the amplitude of ACh-induced currents, occurred at a concentration of 50 microM ACh. 4. Galantamine affects not only the activity of post-synaptic receptors but also the activity of nerve terminals. At a concentration of 1 microM, quantal spontaneous events, recorded in a cholinergic synapse, increased their amplitude, an effect which was independent of the anticholinesterasic activity associated with this compound. The anticholinesterasic effect was recorded in preparations treated with a galantamine concentration of 10 microM. 5. In conclusion, our results show that galantamine enhances human alpha7 neuronal nicotinic ACh receptor activity. It also enhances muscular AChRs and the size of spontaneous cholinergic synaptic events. However, only a very narrow range of galantamine concentrations can be used for enhancing effects.
ESTHER : Texido_2005_Br.J.Pharmacol_145_672
PubMedSearch : Texido_2005_Br.J.Pharmacol_145_672
PubMedID: 15834443

Title : Galanthamine pattern in Narcissus confusus plants - Lopez_2003_Planta.Med_69_1166
Author(s) : Lopez S , Bastida J , Viladomat F , Codina C
Ref : Planta Med , 69 :1166 , 2003
Abstract : Galanthamine is an Amaryllidaceae-type alkaloid with acetylcholinesterase inhibitory activity which is used in the treatment of Alzheimer's disease. The distribution of galanthamine and four other alkaloids in different organs of Narcissus confusus plants, as well as the variations occurring during the ontogenic cycle of this plant species, was studied. The five alkaloids were found to be present in all the organs at every stage, with the exception of haemanthamine in senescent flowers. The highest amount of alkaloids occurred in the bulb at the emerging stage, galanthamine being the most abundant, reaching a concentration of up to 2.5 % referred to dry weight.
ESTHER : Lopez_2003_Planta.Med_69_1166
PubMedSearch : Lopez_2003_Planta.Med_69_1166
PubMedID: 14750039

Title : Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts - Lopez_2002_Life.Sci_71_2521
Author(s) : Lopez S , Bastida J , Viladomat F , Codina C
Ref : Life Sciences , 71 :2521 , 2002
Abstract : Amaryllidaceous plants produce pharmacologically active alkaloids, galanthamine being the most interesting for its use in the treatment of Alzheimer's disease as a cholinesterase inhibitor. The aim of this work was to test 23 pure Amaryllidaceae alkaloids and 26 extracts from different species of the genus Narcissus for their acetylcholinesterase inhibitory activity using galanthamine as a reference. Only seven alkaloids, belonging to the galanthamine and lycorine skeleton types, exhibited such an effect, sanguinine being the most active, even more than galanthamine. All the extracts with the highest acetylcholinesterase inhibitory activity contained galanthamine except that of N. assoanus, a lycorine type alkaloid-bearing species.
ESTHER : Lopez_2002_Life.Sci_71_2521
PubMedSearch : Lopez_2002_Life.Sci_71_2521
PubMedID: 12270757

Title : Genetic and epigenetic control of the Na-G ion channel expression in glia - Gautron_2001_Glia_33_230
Author(s) : Gautron S , Gruszczynski C , Koulakoff A , Poiraud E , Lopez S , Cambier H , Dos Santos G , Berwald-Netter Y
Ref : Glia , 33 :230 , 2001
Abstract : The Na-G ion channel, previously cloned from a rat astroglia cDNA library, belongs to a new family of ion channels, related to but distinct from the predominant brain and muscle fast voltage-gated Na(+) channels. In vivo, the corresponding transcripts are widely expressed in peripheral nervous system neurons and glia, but only in selected subpopulations of neuronal and glia-like cells of the central nervous system. In the present report, we show that Na-G messenger RNA level in astrocyte and Schwann cell cultures is modulated in a cell-specific manner by several growth factors, hormones, and intracellular second messengers pathways. Striking changes in transcript level were observed in the two types of glia in response to protein-kinase A activation and to treatment with the neuregulin glial growth factor, indicating regulation of the Na-G gene by neuroglial signaling. By transient transfection of Na-G/reporter constructs into cultured cells, we show that a short genomic region, encompassing the first exon and 375 bp upstream, bears a high glial-specific transcriptional activity while part of the first intron behaves as a negative regulatory element. In vivo footprinting experiments revealed binding of glial-specific nuclear factors to several sites of the Na-G promoter region. Finally, Na-G/reporter constructs are shown to sustain a low but reproducible transcriptional response to cAMP, accounting in part for the elevation in mRNA level elicited by cAMP in Schwann cells and its reduction in astrocytes.
ESTHER : Gautron_2001_Glia_33_230
PubMedSearch : Gautron_2001_Glia_33_230
PubMedID: 11241741